ArticleFrontiers in nutrition2025
Structure modification of luteolin and the influence of its derivatives on biological activities.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of plant flavonoids and selenium on pancreatic hormones and glucose homeostasis in autoimmune thyroiditis.Experimental animals · 2026Article
- Flavonoids as Nutraceuticals to Treat Inflammatory Diseases: Focusing on Quercetin, Kaempferol, Luteolin, Apigenin, Epicatechin and Their Effects on Hepatic, Nervous, and Pulmonary Systems.Foods (Basel, Switzerland) · 2026Review
- Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma.International journal of molecular sciences · 2026Review
- Luteolin in osteoarticular diseases: a review of preclinical studies and translational perspectives.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This research aims to synthesize luteolin derivatives from hemp seeds by means of chemical synthesis, improve the synthesis process, simplify the procedure, and increase the yield to obtain new luteolin derivatives. Additionally, anti-inflammatory and antioxidant activities of hemp seed extracts and newly synthesized substances are tested to screen out substances with high anti-inflammatory and antioxidant activities. Methods: Using luteolin as the raw material, acetyl, propionyl, and butyryl groups are introduced into the molecular structure of luteolin. A one-pot synthesis method is employed to modify the hydroxyl groups at positions 5, 7, 3', and 4' to obtain six new luteolin acyl derivatives. The molar ratio of reaction conditions is 1:4. Pyridine (20 mL) is used as the solvent, and the reaction is carried out at 25°C and 110°C. Exploring the anti-inflammatory and antioxidant activities of luteolin and its derivatives by establishing a psoriasis model. Results: The products are separated and purified by column chromatography and recrystallization, and six new luteolin acyl derivatives were synthesized: namely, 7,3',4'-tri-O-acetylated luteolin (A), 7,3',4'-tri-O-propionylated luteolin (B), 7,3',4'-tri-O-butyrylated luteolin (C), 5,7,3',4'-tetra-O-acetylated luteolin (D), 5,7,3',4'-tetra-O-propionylated luteolin (E), and 5,7,3',4'-tetra-O-butyrylated luteolin (F). By establishing a psoriasis like mouse model, the results showed that luteolin and its derivatives have good therapeutic effects on inflammation and antioxidation. Discussion: Six new acyl derivatives of luteolin were synthesized through structural modification, which improved their solubility and bioavailability. In the psoriasismodel, it has been proven that acyl derivatives of luteolin have anti-inflammatory and antioxidant activities, and have a relieving effect on psoriasis.Provide theoretical basis and potential treatment strategies for the future treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.